EU OKs Bristol-Myers, AstraZeneca diabetes drug

(AP)—Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC say their experimental diabetes pill has gotten its first major approval, in the European Union.

Forxiga (for-SEE'-gah), a once-a-day pill for adult Type 2 diabetes patients, is the first drug approved in a new class called SGLT2 inhibitors.

Known chemically as dapagliflozin (da-pah-GLEH'-flo-zihn), Forxiga works independently of insulin to remove excess blood sugar from the body differently than other Type 2 .

It can be taken alone or with insulin or other medicines that lower blood sugar.

Last January, the U.S. said it wouldn't approve the drug without more data. Bristol-Myers says the two drugmakers now plan to provide additional data from ongoing patient studies and reapply for approval in mid-2013.


Explore further

FDA questions safety of experimental diabetes drug

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: EU OKs Bristol-Myers, AstraZeneca diabetes drug (2012, November 14) retrieved 9 May 2021 from https://medicalxpress.com/news/2012-11-eu-oks-bristol-myers-astrazeneca-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments